SPRC Patents

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Published August 07, 2025 at 11:32 AM

TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of an international patent application under the Patent Cooperation Treaty (PCT).

Related Questions

How does this collaboration with Clearmind Medicine impact SciSparc's competitive positioning in the obesity and diabetes market? How does the announced therapy compare to existing treatments for obesity and high blood sugar in terms of efficacy and safety? How will the international patent application affect SciSparc's valuation and future cash flows? Will the patent filing under the PCT provide broad protection against competitors, and what jurisdictions are being targeted? What is the potential impact on SciSparc's pipeline diversification and overall risk profile? What are the potential market size and revenue upside if the therapy successfully reaches commercialization? How might this news influence the stock price of SciSparp (SPRC) and Clearmind (CMND) in the short term? Are there any regulatory or safety concerns that could delay or jeopardize the development of the novel combination therapy? What is the expected timeline for clinical development and potential FDA/EMA approval of the combination therapy? What are the financial terms of the SciSparc‑Clearmind collaboration, including any milestone payments or royalty structures?